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ABSTRACT 
Inhibition of Cyclosporin A Induced Gingival Overgrowth 
by Azithromycin through Phagocytosis: An In vivo and In vitro Study 
 
Background: The objective of the present study was to investigate the effect of 
cyclosporin A (CsA) and azithromycin (AZI) on collagen metabolism in the 
gingiva of rats. 
Methods: Fifty 6-week-old male Sprague-Dawley(SD) rats(weight 120 to 
150g) were randomly distributed into five groups. All groups received various 
drugs via gastric feeding for 7weeks. The first group(Mo group) received 
mineral oil for 7weeks as a control; the CsA group received CsA in mineral oil 
for 7weeks(dosage 30mg/kg); the CsA/Mo group received CsA in mineral oil 
for 6weeks and mineral oil only for the seventh week; the CsA/AZI group 
received CsA in mineral oil for 6weeks and AZI(dosage 10mg/kg) in mineral 
oil simultaneously with CsA in the seventh week; and the Mo/AZI group 
received mineral oil for 6weeks and AZI in mineral oil for the seventh week. 
All animals were sacrificed for clinical and histological analyses. Gingival 
fibroblasts were cultured at the fourth passage, and the amount of collagen was 
measured. Type I collagen and collagenase mRNA were measured by reverse 
transcription-polymerase chain reaction. Collagen phagocytosis assay also was 
performed. 
Results: Clinically, CsA induced gingival overgrowth in rats, whereas AZI 
reduced gingival overgrowth. Histological results of the CsA group showed a 
marked increase of tissue volume compared to the other groups. High collagen 
amounts were found when gingival overgrowth was induced. However, type I 
collagen mRNA and collagenase mRNA expressions did not statistically differ 
among groups. Phagocytosis assay showed that CsA decreased phagocytic 
activity of gingival fibroblasts, whereas AZI increased the activity. These 
results suggest that the induction and reduction of CsA-induced gingival 
overgrowth were closely associated with phagocytic activity. 
Conclusion: Cyclosporin A decreases collagen degradation by lowering 
phagocytic activity of rat gingival fibroblasts. Azithromycin partially 
compensates for this lowered phagocytic activity.  
                                                                            
KEY WORDS: Cyclosporin A, Azithromycin, Collagen metabolism, 
Phagocytosis, Reverse transcription-polymerase chain reaction. 
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Ⅰ.INTRODUCTION 
 
Cyclosporin A(CsA) has been widely used to prevent organ transplant rejection 
and to treat various immuno-diseases3,6,37 due to its suppressive effect on 
specific T lymphocytes and inhibition of certain lymphokines.4,5 Despite the 
effectiveness of CsA, its clinical application is limited due to various side 
effects such as cardiotoxicity, nephrotoxicity, and gingival overgrowth.13,34,36,43 
   Previous reports showed that this gingival overgrowth was due to 
accumulation of extracellular collagenous component.2 Collagen is precisely 
balanced by collagen synthesis and degradation to maintain a steady state.35 
Thus, gingival overgrowth is a manifestation of the loss of homeostasis, 
resulting in a surplus of matrix proteins, particularly collagen.25 There are two 
pathways of collagen degradation: one is the extracellular pathway involving 
secretion of collagenase, and the other is the intracellular pathway involving 
phagocytosis.8,25,27,35 Normal collagen turnover is primarily controlled by the 
collagenase-independent route(intracellular pathway), while the collagenase-
mediated route(extracellular pathway) predominates during inflammation. 
Despite many investigations, the etiology of CsA-induced gingival 
overgrowth1,12,17,18,32,28 remains unknown. 
   Clinically, Azithromycin(AZI) has been reported to reduce drug-induced 
gingival overgrowth.7,24,28,41,42 AZI is a macrolide antibiotic of the azalide 
subclass with a long half-life that suppresses protein synthesis of both Gram-
positive and Gram-negative aerobes. It has been reported that CsA-induced 
gingival overgrowth can be effectively treated with a 5-day course of AZI 
while maintaining CsA therapy.26,30,39 However, the mechanism of this 
inhibitory effect has not been identified. 
   Fu et al. established a Sprague-Dawley(SD) rat model of CsA-induced 
gingival overgrowth in which macroscopic overgrowth can be observed as 
early as day 15 after first administering CsA.9-11 We used this rat experimental 
model to eliminate major variables such as inflammation, which allowed us to 
better clarify the etiology of CsA-induced gingival overgrowth. 
   In the present study, we induced gingival overgrowth by CsA and then 
reduced the overgrowth by cessation of CsA or administration of AZI in SD 
rats in vivo. We also measured the amount of collagen in vitro. The objective 
was to investigate the effect of CsA and AZI on collagen metabolism in the 
gingiva of rats. 
 
 
 
 
 
 
 
 
 
 
 
 
Ⅱ. MATERIALS AND METHODS 
Experimental Design 
Fifty 6-week-old male Sprague-Dawley rats(weight 120 to 150g) were 
randomly distributed into five groups. The Mo group received mineral oil(1ml) 
daily via gastric feeding for 7weeks as a control. The CsA group received 
CsA*(dosage 30mg/kg) in mineral oil via gastric feeding for 7weeks. The 
CsA/Mo group received CsA(dosage 30mg/kg) in mineral oil daily via gastric 
feeding for 6weeks, and mineral oil only for the seventh week. The CsA/AZI 
group received CsA(dosage 30mg/kg) in mineral oil daily via gastric feeding 
for 6weeks and AZI†(dosage 10mg/kg) in mineral oil simultaneously with CsA 
in the seventh week. The Mo/AZI group received mineral oil for    --------------
---------------------------------------------------------------------------------------------------- 
*
 Sandimmun Neoral, Novartis, Basel, Switzerland. 
†
 Zithromax, Pfizer, Seoul, Korea. 
6weeks, and AZI(dosage 10mg/kg) in mineral oil for the seventh 
week( Figure 1). Rats were weighed daily, and the drug amounts were 
adjusted to maintain constant dosage. The animals were maintained in plastic 
cages in a room with 12-hour day/night cycles and an ambient temperature of 
25°C, and allowed free access to water ad libitum and standard laboratory 
pellets. Animal selection and management followed protocols approved by the 
Animal Care and Use Committee, Yonsei Medical Center, Seoul, Korea. 
 
Clinical Analysis 
To record the sequence of gingival changes in the mandibular anterior region, 
alginate impressions under general anesthesia, with an intramuscular 
injection(5mg/kg body weight) consisting of ketamine hydrochloride‡ and    
------------------------------------------------------------------------------------------------------------------      
‡
 Ketalar, Yuhan Co., Seoul, Korea. 
stone casts, were made every 2weeks. The mesiodistal width, labio-lingual 
width, and vertical height at the interdental papilla level and the keratinized 
gingiva level in the mandibular anterior segment were measured according to 
the method of Fu et al.11 on the stone cast with a stereomicroscope§( Figure 
2). 
 
Histological Analysis 
Rats were sacrificed by using CO2 gas at the end of the experiment, and the 
jaws were immediately dissected and fixed in 10% neutral formalin. Following 
decalcification in 5% hydrochloric acid, 3µm serial sections were made on the 
labio-lingual aspects of the central incisor area. Routine hematoxylin-eosin 
staining was performed as described previously,23 and light microscopic 
examination§ was performed. 
------------------------------------------------------------------------------------------------------------------
§
 Olympus, Olympus Co., Tokyo, Japan. 
Gingival Fibroblast Culture 
Rat gingival fibroblasts from gingival biopsies were seeded into T-25 flasks|| at 
fourth passage and grown in alpha-minimal essential medium(α-MEM) ¶ 
supplemented with 10% fetal bovine serum(FBS) ¶ and antimycotic-antibiotic 
solution.20 
 
Collagen assay 
The amount of collagen in the five groups was assessed using a commercially 
available kit. # Briefly, triplicate cultures of confluent cells in 96-well 
plates(1×104cells/well) were incubated in the presence of 5% FBS. Test 
samples(100µl) from each well were added to 100µl dye reagent in 1.5µl tubes. 
------------------------------------------------------------------------------------------------------------------
||
 
Nalge, Nunc International, Rochester, NY. 
¶
 Gibco BRL Life Technologies, Gaithersburg, MD. 
#
 Sircol collagen assay kit, Biocolor Ltd., Galway, Ireland. 
The tubes were mixed gently at room temperature for 30minutes and then 
centrifuged for 10minutes at 10,000rpm. The supernatant was drained off, and 
100µl of the alkali reagent was added. Samples were assessed under 530nm 
wavelength using an enzyme-linked immuno-sorbent assay reader. ** 
 
Reverse Transcription-Polymerase Chain Reaction(RT-PCR) for Type I 
Collagen and Collagenase 
Gingival fibroblasts were seeded onto 60mm dishes at a density of 2 × 
105cells/dish. At confluence, total RNA was extracted using a reagent†† 
according to the manufacturer’s instructions. The concentration of the RNA 
was determined by spectrophotometry measuring optical density(OD) at 260  
------------------------------------------------------------------------------------------------------------------      
**
 DYNATECH Lab., Chantilly, VA. 
††
 TRIZOL, Gibco BRL Life Technologies. 
and 280nm. RT-PCR for type I collagen and collagenase mRNA was carried 
out with a commercial RNA PCR kit. ‡‡ Total RNA (1µg) isolated from each 
sample was used as a template for cDNA synthesis. Reverse transcription of 
total RNA was performed for 15minutes at 42°C in a reaction buffer containing 
1mM dNTP mixture, 1µM antisense primer, and 0.25U/µl reverse transcriptase. 
The cDNA was used immediately or stored at –20°C until used.   The cDNA 
was amplified by PCR in 80µl reaction mixture containing 20µl of each cDNA. 
The reaction mixture contained 2.5U/100µl of Taq polymerase, ‡‡ 1X reaction 
buffer and 0.2µM of sense primer mix. PCR was performed for 30cycles of 
94°C for 1minute, 60°C for 1minute, 72°C for 1minute, and the tubes cooled to 
4°C in a thermocycler. §§ PCR conditions and the sequences of the primers 
used are shown in Table 1.                    ----------------------------------------
-------------------------------------------------------------------------
‡‡
 Takara RNA PCR kit, Takara 
Shuzo Co., Ltd., Shiga, Japan. 
§§
 T gradient, Biometra, Göttingen, Germany.                                
Table 1. PCR oligonucleotide primers  
 
Primers Sequence 
Size 
(bp) 
A.T. 
(°C)  
Thermal 
cycles 
Sense 5’ AACGATGGTGCCAAGGGTGAT 3’ 
Collagen18 
Anti 5’ ATTCTTGCCAGCAGGACCAAC 3’ 
1077 60 30 
Sense 5’ AGTTGGACTCACTGTTGGTCC 3’ 
Collagenase18 
Anti 5’ ACAGTTCAGGCTCAACCTGCT 3’ 
928 60 30 
Sense 5’ AACCGCGAGAAGATGACCCAGATCATGTTT 3’ β-actin15 
Anti 5’ AGCAGCCGTGGCCATCTCTTGCTCGAAGTC 3’ 
351 60 30 
 
 
 
 
 
 
 After amplification, 16µl of each PCR product was analyzed by 1.3% agarose 
gel electrophoresis; the bands were visualized by ethidium bromide staining; 
and the gels were photographed using a gel documentation system||||  under 
ultraviolet light. 
 
Phagocytosis Assay Using Flow Cytometer 
Phagocytosis assay was measured using 2.0µm fluorescent latex beads¶¶ coated 
with soluble bovine type I collagen according to a previously described 
method.19,21,25 Gingival fibroblasts were seeded onto six-well plates at a density 
of 4×104cells/well. At confluence, fibroblasts were incubated with coated 
beads(bead:cell ratio, 4:1) for 16hours, and the cells were washed in    ---------
------------------------------------------------------------------------------------------------------- 
||||Gel Doc 1000, Bio-Rad, Hercules, CA.  
PBS at 37°C then detached with 0.01% trypsin¶ at 37°C for 10minutes. They 
were resuspended in 1ml PBS and kept at 4°C. The trypsin was neutralized by 
the addition of an equal volume of medium containing 15% FBS, washed in 
PBS, and fixed for 30minutes at 4°C in 80%(v/v) ethanol added drop-wise to 
the cells. For flow cytometry, the cells were analyzed at a rate of 
200cells/second on a flow cytometer## with 488nm excitation and emission 
measured with a 530/30band pass filter. Populations of phagocytic and non-
phagocytic cells were verified by cell sorting. The percentage of phagocytic 
cells was determined by the formula([number of cells with internalized 
beads/total number of cells]×100). 
-----------------------------------------------------------------------------------------------------------------
¶¶
 
Molecular Probes Inc., Eugene, OR.  
##
 FACS Calibur, Becton-Dickinson Immunocytometry System, San Jose, CA. 
 Statistical Analysis 
Statistical differences were determined by analysis of variance and post-hoc t 
test for multiple comparisons. Statistical significance was determined at the P 
<0.05 level. 
 
 
 
 
 
 
 
 
  
Ⅲ. RESULTS 
Clinical and Histological Analyses 
Gingival overgrowth was observed in the three groups that had received CsA. 
The overgrowth in the mesiodistal and labio-lingual width significantly 
increased at the interdental papilla level at 4weeks, while the vertical height 
increased markedly at the keratinized gingiva level at 6weeks. After 6weeks, 
gingival overgrowth decreased in the CsA/Mo group and CsA/AZI group. 
These two groups represented similar patterns despite continuous CsA 
administration in the CsA/AZI group( Table 2 and Table 3). 
   Histological examination of the CsA group showed marked increase of tissue 
volume compared to the other groups. There were few inflammatory cells in 
the overgrown gingiva( Figure 3). 
 Table 2. Gingival changes at the interdental papilla level 
 
Group Baseline 2 wks 4 wks 6 wks 7 wks 
 Mesiodistal width(㎜) 
Mo 1.36±0.12 1.46±0.26 1.5±0.15 1.53±0.10 1.54±0.09 
CsA 1.34±0.11 1.57±0.16 1.99±0.13* 2.08±0.21* 2.20±0.20* 
CsA/Mo 1.31±0.13 1.59±0.17 1.83±0.05* 2.14±0.19* 1.62±0.16 
CsA/AZI 1.32±0.12 1.58±0.18 1.84±0.05* 2.20±0.13* 1.52±0.11 
Mo/AZI 1.30±0.10 1.48±0.13 1.54±0.11 1.54±0.11 1.54±0.09 
 Labiolingual width(㎜) 
Mo 1.93±0.13 2.04±0.13 2.26±0.16 2.32±0.18 2.38±0.19 
CsA 1.99±0.12 2.26±0.12 2.50±0.21* 2.63±0.09* 2.72±0.27* 
CsA/Mo 1.69±0.11 2.23±0.10 2.38±0.13 2.52±0.08* 2.38±0.19 
CsA/AZI 1.70±0.09 1.98±0.23 2.27±0.08 2.54±0.09* 2.28±0.16 
Mo/AZI 1.76±0.09 1.98±0.13 2.34±0.15 2.36±0.13 2.38±0.15 
 Vertical height(㎜) 
Mo 1.26±0.15 1.39±0.14 1.39±0.19 1.45±0.13 1.46±0.13 
CsA 1.23±0.08 1.40±0.11 1.53±0.16 1.66±0.23 1.72±0.18* 
CsA/Mo 1.10±0.12 1.46±0.05 1.48±0.28 1.77±0.14 1.40±0.14 
CsA/AZI 1.15±0.10 1.38±0.12 1.42±0.11 1.62±0.25 1.40±0.07 
Mo/AZI 1.18±0.11 1.42±0.08 1.42±0.04 1.46±0.11 1.47±0.12 
 
* Statistically significant differences compared with control group(Mo group) 
at p<0.05.   
Table 3. Gingival changes at the keratinized gingiva level 
 
Group Baseline 2 wks 4 wks 6 wks 7 wks 
 Mesiodistal width(㎜) 
Mo 4.00±0.34 4.54±0.21 4.56±0.18 4.58±0.12 4.60±0.16 
CsA 4.04±0.21 4.56±0.17 4.87±0.18 5.00±0.37 5.04±0.22 
CsA/Mo 3.80±0.17 4.56±0.19 4.80±0.14 5.04±0.39 4.57±0.30 
CsA/AZI 3.91±0.18 4.49±0.14 4.84±0.26 4.92±0.22 4.44±0.11 
Mo/AZI 3.96±0.19 4.48±0.16 4.55±0.10 4.56±0.05 4.58±0.16 
 Labiolingual width(㎜) 
Mo 3.90±0.24 4.15±0.32 4.22±0.25 4.23±0.24 4.24±0.15 
CsA 3.89±0.21 4.16±0.22 4.42±0.21 5.01±0.16* 4.96±0.09* 
CsA/Mo 3.51±0.28 4.14±0.26 4.30±0.18 4.80±0.23* 4.44±0.15 
CsA/AZI 3.60±0.26 4.08±0.23 4.26±0.17 4.83±0.29* 4.18±0.16 
Mo/AZI 3.66±0.25 4.10±0.35 4.15±0.26 4.22±0.30 4.30±0.16 
 Vertical height(㎜) 
Mo 4.04±0.24 4.37±0.38 4.48±0.38 4.64±0.30 4.80±0.23 
CsA 4.07±0.18 4.68±0.32 4.98±0.21 5.34±0.38* 5.82±0.16* 
CsA/Mo 4.03±0.19 4.76±0.13 4.63±0.21 5.56±0.38* 5.12±0.18 
CsA/AZI 3.92±0.17 4.72±0.10 4.76±0.09 5.50±0.12* 5.32±0.22 
Mo/AZI 3.90±0.20 4.32±0.40 4.53±4.53 4.54±0.36 4.50±0.12 
 
* Statistically significant differences compared with control group(Mo group) 
at p<0.05.   
Collagen Assay 
The amount of collagen in the CsA group statistically significantly increased 
compared to the other groups. The amount of collagen in the CsA/Mo and 
CsA/AZI groups increased compared to the Mo and Mo/AZI groups( Figure 
4). These results were consistent with the clinical observations of gingival 
overgrowth. 
 
RT-PCR for Type I Collagen and Collagenase 
Type I collagen mRNA was detected using RT-PCR; however, there were no 
significant differences among any of the groups in terms of band density. 
Collagenase mRNA levels were almost identical( Figure 5). These results 
indicated that CsA and AZI have little effect on type I collagen or collagenase 
mRNA. 
Phagocytosis Assay 
The percentage of phagocytic cells in the Mo group was 47.78%, and in the 
Mo/AZI group 51.08%. The Mo/AZI group showed the highest percentage of 
phagocytic cells, but this was not statistically significant. The percentage of 
phagocytic cells in the CsA group was 25.78%, which was statistically 
significantly decreased compared to the other groups. The percentages in the 
CsA/Mo and CsA/AZI group were 37.39% and 37.04%, respectively. These 
two groups showed nearly the same values; they also showed a decreased 
percentage of phagocytic cells, although it was still significantly increased 
compared to the CsA group( Figure 6). These results showed that CsA 
decreased phagocytic activity of gingival fibroblasts, whereas AZI increased 
the activity. 
  
Ⅳ. DISCUSSION 
CsA is known to cause gingival overgrowth due to changes in collagen 
metabolism.13,34,36,43 Collagen metabolism is precisely regulated by 
homeostatic balance between collagen synthesis and degradation.35 However, it 
is not known exactly what effect CsA has on collagen metabolism.16,29,33,40 
   There are some difficulties in investigating the etiology of CsA-induced 
gingival overgrowth in humans. The genetic capacity of the host to metabolize 
administered drugs, the responsiveness of gingival tissue to the drugs, and the 
preexisting gingival condition may differ among individuals.29 Therefore, 
many investigators have attempted to develop a controlled animal model of 
CsA-induced gingival overgrowth. The Sprague-Dawley rat model used in the 
present study is suitable for investigating the etiology of CsA-induced gingival 
overgrowth. These rats, although they were not inbred, respond quite uniformly 
to CsA.31 Humans, on the other hand, respond differently to similar treatment 
protocols.6,13,36 In their review article on rat model studies, Nishikawa et al. 
reported that the incidence of macroscopic gingival overgrowth was 100% after 
a relatively short administration of drug.29 The present results are consistent 
with this. Preexisting gingival conditions such as inflammation were controlled 
in this model. This is important because inflammation plays a major 
aggravating role in the process of gingival overgrowth.29 In the present study, 
histological examination showed few inflammatory cells in the groups. 
   We demonstrated in the present study that collagen accumulation in CsA-
induced gingival overgrowth is not caused by increased synthesis of collagen 
but by decreased degradation, since CsA did not affect the synthesis of type I 
collagen at the transcription level. Specifically, CsA decreased collagen 
degradation through an extracellular phagocytosis-mediated pathway, which 
may be an important event in the normal turnover of collagen.1,17,35 
   In addition, cessation of CsA or administration of AZI resulted in significant 
inhibition of CsA-induced gingival overgrowth. These results are in agreement 
with previous clinical reports showing that AZI can treat CsA-induced gingival 
overgrowth effectively despite continuous administration of 
CsA.7,24,26,28,30,39,41,42 
   Clinically, AZI has been reported to be highly effective in treating CsA-
induced gingival overgrowth. 7,24,26,28,30,39,41,42 These results imply that AZI has 
an inhibitory effect on CSA-induced gingival overgrowth. However, there are a 
few reports concerning the inhibitory mechanism of AZI.14,22,41 Three possible 
mechanisms could be inferred, the first of which is the inherent drug effect of 
AZI. Citterio et al. suggested that the effects of AZI on gingival overgrowth 
might be related to its antibiotic activity, killing oral bacteria, reducing local 
inflammation, and suppressing protein synthesis in fibroblasts.7 The reason 
why only AZI affects CsA-induced gingival overgrowth needs to be clarified. 
In the present study, AZI alone had no effect on gingiva or gingival fibroblasts; 
only when CsA was being administered did AZI decrease gingival overgrowth 
and increase phagocytic activity of gingival fibroblasts. These findings suggest 
that there might be an interaction between CsA and AZI. The second 
possibility is that AZI inhibits the inherent effects of CsA. Some researchers 
reported the upregulating effect of AZI on the serum levels of CsA,22 while 
others reported no effects.14 The interaction between AZI and CsA is 
controversial, but no studies could be found to support this second mechanism. 
The third possibility is that AZI is associated with the inhibition of 
phagocytosis induced by CsA. This possibility corresponds to the present 
results, in which AZI significantly increased the lowered phagocytic activity 
induced by CsA. 
   CsA is known to be a Ca2+ antagonist. It is noteworthy that CsA, phenytoin, 
and nifedipine, the three drugs that induce gingival overgrowth, are all Ca2+ 
antagonists. These findings suggest that gingival overgrowth may arise from a 
common pathogenetic basis in association with Ca2+. Kataoka et al. proposed 
that CsA may block the influx of Ca2+, thus inhibiting phagocytosis, which 
clinically results in gingival overgrowth.17 This suggestion has been supported 
by several articles.1,18,38 Further studies concerning the changes in the influx of 
Ca2+ are necessary to understand the regulatory mechanisms of AZI on CsA-
induced gingival overgrowth. 
   In summary, CsA-induced gingival overgrowth is a condition of collagen 
accumulation that can be treated by AZI therapy. The collagen accumulation is 
not caused by increased synthesis of collagen but rather by decreased 
degradation. Based on the present results, phagocytosis is thought to be the 
principal pathway of collagen degradation in CsA-induced gingival overgrowth. 
Moreover, treatment with AZI appears to restore part of the phagocytosis 
mechanism. 
   In conclusion, our results suggest that cyclosporin A decreases collagen 
degradation by lowering phagocytic activity of rat gingival fibroblasts, and that 
AZI partially compensates for this lowered phagocytic activity. 
 
 
 
 
 
 
 
 
 
  
 
Ⅴ. CONCLUSION 
Cyclosporin A decreases collagen degradation by lowering phagocytic activity 
of rat gingival fibroblasts. Azithromycin partially compensates for this lowered 
phagocytic activity. 
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FIGURE LEGENDS 
Figure 1. Study design during 7-week experiment. 
CsA and AZI were diluted in mineral oil.  
 
Figure 2. Clinical measurement of gingival changes. 
The measurements of mesiodistal width(MD), labio-lingual width(LL), and 
vertical height(VH) of the interdental papilla level(i) and keratinized gingiva 
level(k) in the region of the mandibular incisors(This figure is reprinted with 
permission from Quintessence Publishing Co., Inc.). 
 
Figure 3. Histological views of rat gingival tissue in the mandibular central 
incisor area. Photomicrographs(×40) of lingual gingiva from 13-week-old 
Sprague-Dawley rats fed various drugs: A) Mo group, B) CsA group, C) 
CsA/Mo group, D) CsA/AZI group, and E) Mo/AZI group.  
 
Figure 4. Amount of collagen in rat gingival fibroblasts.  
Collagen amount in the CsA group statistically significantly increased 
compared to the other groups. *Statistically significant differences compared to 
the Mo and Mo/AZI groups at P <0.05. †Statistically significant differences 
compared to the other groups at P <0.05. Experiments were conducted at least 
three times, and similar results were obtained. 
 
Figure 5. RT-PCR analysis of type I collagen and collagenase mRNAs in the 
rat gingival fibroblasts.  
Note that there are no differences in the band density among any of the groups. 
Experiments were conducted at least three times, and similar results were 
obtained.  
 
Figure 6. Flow cytometry of rat gingival fibroblasts with internalized beads.  
A) Mo group, B) CsA group, C) CsA/Mo group, D) CsA/AZI group, and E) 
Mo/AZI group. The CsA group showed a small number of phagocytic 
fibroblasts compared to the other groups. *Statistically significant differences 
compared to the Mo and Mo/AZI groups at P <0.05.†Statistically significant 
differences compared to the other groups at P <0.05. Experiments were 
conducted at least three times, and similar results were obtained. 
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Figure 4. Collagen amount in rat gingival fibroblasts.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 5. RT-PCR analysis of type I collagen and collagenase mRNAs in the 
rat gingival fibroblasts.  
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Figure 6. Flow cytometry of rat gingival fibroblasts with internalized beads. 
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국문 요약 
Inhibition of Cyclosporin A Induced Gingival Overgrowth  
by Azithromycin through Phagocytosis: An In vivo and In vitro Study 
 
면역 억제제로 널리 사용되는 싸이클로스포린(Cyclosporin A, CsA)은 여러 가지 
부작용을 나타내고 있는데 치과와 관련된 부분이 치은 과증식이다. 임상적으로는 
아지스로마이신 (Azithromycin)이 이를 감소시킨다는 보고가 있으나, 상기 두 가지 
약물이 어떠한 기전으로 치은에 영향을 주는지는 아직까지 명확치 않다. 본 연구의 
목적은 백서 치은의 교원질 대사에 미치는 싸이클로스포린과 아지스로마이신의 
영향을 알아보고자 함이다. 수컷 백서(Sprague-Dawley Rat, 무게 120-150g) 50마리를 
무작위로 5개 군으로 분류하여 7주 간 각기 다른 약물을 위에 투여하였다. 첫 번째 
군(Mineral oil 군, Mo 군)은 대조군으로 7주 간 미네랄 오일을 투여하였다; CsA 
군은 7주 간 미네랄 오일로 희석한 싸이클로스포린(농도 30㎎/㎏)을 투여하였다; 
CsA/Mo 군은 6주 간 미네랄 오일로 희석한 싸이클로스포린(농도 30㎎/㎏)을 
투여하다가 7주 째는 미네랄 오일만을 투여하였다; CsA/AZI 군은 6주 간 미네랄 
오일로 희석한 싸이클로스포린(농도 30㎎/㎏)을 투여하다가 7주 째는 미네랄 
오일로 희석한 싸이클로스포린(농도 30㎎/㎏)과 아지스로마이신(농도 10㎎/㎏)을 
함께 투여하였다; Mo/AZI 군은 6주 간 미네랄 오일을 투여하다가 7주 째는 미네랄 
오일로 희석한 아지스로마이신 
(농도 10㎎/㎏)을 투여하였다. 2주 간격으로 모든 군의 하악 전치부 인상을 
채득하여 임상적 변화를 계측하였다. 7주 후 모든 군의 동물들은 희생하여 
조직학적 검사 및 세포 배양을 시행하였다. 치은 섬유아세포는 4세대까지 배양하여 
교원질 양을 측정하였고, I형 교원질과 교원질 분해 효소에 대한 역전사 효소 연쇄 
반응(Reverse Transcription Polymerase Chain Reaction, RT-PCR)을 시행하였다. 또한, 
교원질 탐식 작용도 분석하였다. 
임상적으로, 싸이클로스포린은 백서 치은 과증식을 일으킨 반면, 아지스로마이신은 
치은 과증식을 감소시켰다. 조직학적 결과를 볼 때 싸이클로스포린 군은 다른 
나머지 군에 비해 현저한 치은 조직의 과증식을 나타내었다. 또한, 치은 과증식이 
나타난 군에서는 교원질의 양이 증가되어 있음을 알 수 있었다. 그러나, I형 
교원질과 교원질 분해 효소에 대한 전사 리보핵산 발현은 모든 군에서 
통계학적으로 차이가 없었다. 탐식 작용 분석에서 싸이클로스포린은 치은 
섬유아세포의 탐식 활성을 저하시킨 반면 아지스로마이신은 활성을 증가시켰다. 
이러한 결과를 종합할 때 싸이클로스포린 유도 치은 과증식은 탐식 작용과 
밀접하게 연관되어 있다고 사료된다. 
결론적으로, 싸이클로스포린은 백서 치은 섬유아세포의 탐식 활성을 
저하시킴으로써 교원질을 감소시키는 반면, 아지스로마이신은 저하된 탐식 활성을 
부분적으로 보상한다.  
                                                                                      
핵심되는 말: 싸이클로스포린, 아지스로마이신, 교원질, 탐식 작용, 역전사 효소 
연쇄 반응 
 
